Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

This is a open-label (all people know the identity of the intervention), single arm,
multicenter study. The study will consist of a screening phase up to 4 weeks, open-label
treatment phase of 12 weeks, and post-treatment follow up phase up to 24 weeks after end of
treatment. Approximately 100 participants will receive 150 mg simeprevir in combination with
400 mg sofosbuvir once dailyfor 12 weeks. Safety evaluations will include assessment of
adverse events, clinical laboratory tests, vital signs, and physical examination. The
maximum study duration for each participant will be approximately 40 weeks.

Inclusion Criteria:

- Hepatitis C virus (HCV) genotype 1 infection (confirmed at screening).

- HCV ribonucleic acid (RNA) greater than 10,000 IU/mL at screening

- Treatment-experienced participants must have at least 1 documented previous course of
interferon-based regimen with or without ribavirin

- Participants must have an hepatic imaging procedure (ultrasound, computerized
tomography scan or magnetic resonance imaging scan) within 6 months prior to the
screening visit (or between screening and Day 1) with no findings suspicious for
hepatocellular carcinoma

- Participant must be willing and able to comply with the protocol requirements

- Participants with liver cirrhosis

Exclusion Criteria:

- Evidence of clinical hepatic decompensation (history or current evidence of ascites,
bleeding varices or hepatic encephalopathy)

- Infection/co-infection with HCV non-genotype 1

- Co-infection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or
HIV-2) (positive HIV-1 or HIV-2 antibodies test at screening)

- Co-infection with hepatitis B virus (hepatitis B-surface-antigen positive)

- Previously been treated with any direct acting anti-HCV agent (approved or
investigational) for chronic HCV infection